GlassScriptPhysician profile
Justin R Wasserman
NPI 1043453970
$9,647.74
in general payments reported to CMS, 2019-2025
33 companies · $1,680 in 2025
The $1,680 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $746 · 2021: $1,320 · 2022: $1,166 · 2023: $2,321 · 2024: $1,570 · 2025: $1,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,468 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,468.06 |
| Education | $103.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $1,072.21 | 2023-2024 | Zoryve |
| Sun Pharmaceutical Industries INC. | $800.39 | 2019-2025 | Blu-U |
| Abbvie INC. | $740.98 | 2020-2025 | Rinvoq, Skyrizi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $689.99 | 2019-2023 | Siliq |
| Janssen Biotech, INC. | $616.96 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Pfizer INC. | $601.06 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $580.56 | 2019-2025 | |
| Lilly USA, LLC | $529.05 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Lumenis Be INC | $515.00 | 2025 | M22 |
| Ucb, INC. | $487.11 | 2021-2025 | Bimzelx |
| Amgen INC. | $428.30 | 2020-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $377.98 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Allergan, INC. | $305.67 | 2019-2022 | |
| Epi Health, LLC | $303.89 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $219.36 | 2019-2025 | Dupixent, Libtayo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $191.76 | 2021-2024 | |
| Incyte Corporation | $187.20 | 2022-2024 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.30 | 2022-2024 | Spevigo |
| Vyne Pharmaceuticals INC. | $158.81 | 2021 | |
| Leo Pharma INC. | $97.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $90.76 | 2023-2025 | Sotyktu |
| Revance Therapeutics, INC. | $87.84 | 2024-2025 | Daxxify |
| Almirall LLC | $72.40 | 2019-2024 | Seysara |
| Organogenesis INC. | $61.92 | 2025 | Via Matrix |
| Genentech, INC. | $54.03 | 2023 | Xolair |
| Dermavant Sciences, INC. | $40.25 | 2023 | Vtama |
| Dermira, INC. | $30.50 | 2019 | |
| Kerecis Limited | $26.52 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dusa Pharmaceuticals, INC. | $23.49 | 2019 | |
| Mimedx Group, INC. | $22.37 | 2025 | |
| Genzyme Corporation | $22.16 | 2020 | |
| Strata Skin Sciences, INC. | $18.69 | 2025 | Xtrac |
| Nabriva Therapeutics, Plc | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.